In March 2025, the company declared new programs for the direct-to-purchaser presenting of its Wegovy weight loss drug. The company proven a different pharmacy, termed NovoCare, which might cost customers $499 monthly for access to the drug, fewer than 50 percent the expense of the drug as a result of other pharmaceutical distribution networks.[fif